相关实验视频

Updated: Jul 24, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

对非小细胞肺癌患者的术后化疗进行叶片特异性分析

Xi Lei^1,2, Tong Li^1,2, Fuling Mao^1,2

¹Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.

Cancer medicine

|July 5, 2023

概括

术后化疗改善了非小细胞肺癌 (NSCLC) 阶段II-III的生存率. 然而,它可能不会对IB期NSCLC或特定叶区 (右中/下) 的瘤有好处,这表明应考虑叶区特异性治疗.

科学领域:

医学瘤学医学瘤学
胸部外科手术胸部外科手术
临床研究临床研究

背景情况:

基于西斯的术后化疗是非小细胞肺癌 (NSCLC) 的标准治疗方法,与单独手术相比,改善了生存率.
确定可切除的NSCLC中术前化疗的最佳指示,特别是考虑到瘤位置,仍然至关重要.

研究的目的:

在IB-III期非小细胞肺癌 (NSCLC) 患者中研究术后化疗的疗效.
在可切除的NSCLC中进行围手术化疗效益的叶片特异性分析.

主要方法:

从SEER数据库中对23,844名可切除NSCLC患者 (IB-III阶段) 的回顾性分析.
倾向性得分匹配 (PSM) 用于最大限度地降低比较术后化疗与无辐射疗法的偏差.
卡普兰-梅尔方法和日志级别测试评估了整体存活率 (OS) 的差异.

主要成果:

周围手术化学疗法在IB-III期NSCLC患者的整体生存状况有所改善,无论是在PSM前后.
在IB阶段的NSCLC患者中,术后化疗没有显著的生存益处.
额叶分析显示,右中叶 (II-III阶段) 或右下叶 (III阶段) 的瘤没有生存优势.

结论:

在NSCLC中进行术后化疗的叶片特异性建议是合理的.
术后化疗可能不会为IB期NSCLC或位于右中或右下叶的IB-III期NSCLC提供生存益处.

关键词:

在NSCLCLC中,我们可以看到.在 SEER 数据库中,我们可以看到辅助性化疗是一种辅助性化疗.叶片特定的叶片特定的叶片.新辅助性化疗是一种新辅助性化疗.

更多相关视频

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...